Cartesian Therapeutics
12
3
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
50.0%
6 terminated/withdrawn out of 12 trials
14.3%
-72.2% vs industry average
8%
1 trials in Phase 3/4
400%
4 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Descartes-08 in Autoantibody Myositis
Role: lead
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Role: lead
Descartes-08 for Patients With Systemic Lupus Erythematosus
Role: lead
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Role: lead
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Role: lead
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Role: lead
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Role: lead
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Role: lead
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Role: lead
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Role: lead
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Role: lead
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Role: lead
All 12 trials loaded